Our mission is to improve the lives of patients experiencing life-threatening diseases by the discovery, development and delivery of innovative therapies.
Mentions in press and media 6
| Date | Title | Description |
| 21.06.2025 | Paradigm Therapeutics: A Beacon of Hope for Epidermolysis Bullosa Patients | In the world of biopharmaceuticals, every investment can be a lifeline. Paradigm Therapeutics, based in Mount Pleasant, South Carolina, recently secured an additional $12.6 million from Eshelman Ventures. This funding brings the total inves... |
| 20.06.2025 | Paradigm Therapeutics Receives Additional Investment From Eshelman Ventures | Paradigm Therapeutics, a Mount Pleasant, SC-based biopharmaceutical company, received an additional investment of $12.6M from Eshelman Ventures. It brought the total investment in 2025 for Paradigm Therapeutics to $25.1M. The company intend... |
| 18.06.2025 | Paradigm Therapeutics, Inc. Announces an Additional Investment by Eshelman Ventures, LLC to Expedite Global Development and Global Registration of SD-101, A Topical Therapy for Treatment Across the En... | First Topical Therapy Developed to Treat the Wounds and Lesions on the Entire Skin Surface Across All EB Subtypes Funding to be Used to Accelerate Activities Associated with Increasing Manufacturing Development of SD-101 and Commercial Laun... |
| 06.05.2025 | Paradigm Therapeutics, Inc. Announces Investment by Eshelman Ventures, LLC to Support Completion of Development of SD-101 (Zorblisa™), A Topical Therapy for Treatment Across the Entire Skin Surface of... | First Topical Therapy Developed to Treat the Wounds and Lesions on the Entire Skin Surface Across All EB Subtypes Funding to be Used for Completion of All Activities to Support Planned NDA Submission in the Second Half of 2025, Along with P... |
| 22.08.2023 | Paradigm Therapeutics Acquires Late Stage "Breakthrough Therapy" Designated Therapy for Treatment of All Subtypes of Epidermolysis Bullosa (EB) | 'Topical Therapy for Treating the Wounds and Lesions on the Entire Skin Surface' MT PLEASANT, S.C., Aug. 22, 2023 /PRNewswire/ -- Paradigm Therapeutics Inc., a biopharmaceutical company, today announced the completion of the acquisition of ... |
| - | Paradigm Therapeutics | “Our mission is to improve the lives of patients experiencing life-threatening diseases by the discovery, development and delivery of innovative therapies.” |